Volume 11 Supplement 1

Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Glasgow, UK9-13 November 2008

Page 2 of 8

O231 Cryptogenetic liver disease, steatosis, portal hypertension, transaminitis and antiretrovirals

Authors: S Pol

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O24

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Antiretroviral tolerability and efficacy after switch to saquinavir in PI-experienced patients: 48-week analysis of the German Rainbow Cohort

Authors: C Stephan, H Jaeger, A Carganico, G Knecht, T Lutz, C Mayr, FA Mosthaf, S Koeppe, M Mueller, E Wolf, A Tappe, E Wellmann and H Knechten

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P25

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O232 What's new in hepatitis C?

Authors: V Soriano

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O25

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Tipranavir in highly ARV-experienced patients: efficacy and tolerability results from the French prospective NADIS cohort

Authors: C Allavena, P Flandre, P Pugliese, MA Valantin, J Izopet, R Garraffo, I Poizot, A Cabie, Y Yazdanpanah, L Cuzin, C Duvivier, C Katlama and P Dellamonica

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P26

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O233 Surrogate markers for liver damage (i.e. how can we measure the extent of fibrosis and disease without biopsy)

Authors: M Puoti

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O26

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Reduction in AIDS defining events/deaths with etravirine (ETR; TMC125) compared to placebo: pooled DUET 48-week results

Authors: R Haubrich, J Eron, M Thompson, P Reiss, R Weber, M Peeters, R Van Solingen-Ristea, G Beets, E Voorspoels and G De Smedt

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P27

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O311 Pathogenesis of non-AIDS morbidities in HIV disease and implications for management

Authors: S Deeks

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O27

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Patient retention on antiretroviral therapy programme: risk factor analysis of a Uganda cohort

Authors: EJ Mills, P Olupot-Olupot, C Cooper, J Meadway, H Boorman, A Das and JSO Obbo

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P28

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O312 Cardiovascular disease; HIV, ART, immunodeficiency, pro-inflammation and other factors

Authors: JD Lundgren

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O28

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
INDEED study: final results of an induction treatment strategy with enfuvirtide in treatment failure patients

Authors: J Reynes, I Pellegrin, G Peytavin, M Wirden, B Giffo, C Aquilina, A Pinta, N Pierre, S Kraemer and V Calvez

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P29

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O313 Relation between adverse effects of ARV treatment and underlying risk in number needed to treat to harm (NNTH) – myocardial infarction and abacavir use

Authors: JD Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss and JD Lundgren

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O29

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
CD4+ guided antiretroviral treatment interruption. A meta-analysis

Authors: A De Silvestri, A Boschi, C Tinelli and E Seminari

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P30

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O314 Predicting the short-term risk of diabetes in HIV-infected patients in the D:A:D cohort: the D:A:D study group

Authors: K Petoumenos, E Fontas, SW Worm, R Weber, S De Wit, M Bruyand, CA Sabin, P Reiss, W El-Sadr, A d'Arminio Monforte, N Friis-Møller, JD Lundgren and MG Law

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O30

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Raltegravir therapy in HIV multi-experience patients: safety and efficacy

Authors: P Meraviglia, A Capetti, S Merli, F Mazza, V Micheli and G Rizzardini

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P31

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O321 Management of renal disease in HIV infection for the HIV physician

Authors: I Williams

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O31

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Virological and immunological response to three boosted protease inhibitor regimens

Authors: C Baumgardt, C Stephan, AE Haberl, HR Brodt, M Stuermer, S Klauke, P Gute, M Bickel, P Khaykin, N von Hentig and S Staszewski

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P32

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O322 Bone disease and HIV – together for the long term

Authors: P Mallon

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O32

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Long-term safety and efficacy of nevirapine (NVP)-based antiretroviral therapies

Authors: F Rodriguez-Arrondo, K Aguirrebengoa, J Portu, J Muñoz, MA Garcia, J Goikoetxea, E Martinez, JA Iribarren, N Perez, C Alcarez and B Clotet

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P33

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O323 High HIV viral load inhibits osteoblast function and signalling

Authors: NS Chew, EJ Cotter, PP Doran and WG Powderly

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O33

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Different metabolic and anthropometric characteristics of TVD, CBV or KVX associated with nevirapine: Results from the "NEVIRAPINE COMPANION" cohort

Authors: G Guaraldi, F Adorni, S Zona, N Squillace, G Orlando, C Stentarelli, R Esposito and C Sconiamilio

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P34

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O324 HIV, immune deficiency and malignancy

Authors: AE Grulich

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O34

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Antiretroviral treatment efficacy after mutations reversion during T20 monotherapy, an alternative strategy in multi-failed HIV-1 infected patients

Authors: S Lo Caputo, M Santoro, CSF Ceccherini-Silberstein, V Svicher, P Pierotti, F Vichi, R D'Arrigo, C Gori, CF Perno and F Mazzotta

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P35

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O331 Patterns of viral suppression on cART as predictors of uncontrolled viremia after starting a new antiretroviral after 1 January 2003

Authors: J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala and JD Lundgren

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O35

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programme

Authors: E Florence, S De Wit, A Castagna, E Ribera, AM Hill, R Ryan, H Vanaken, S Marks and Y van Delft

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P36

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O332 Opportunistic infections in immunocompromised but virologically suppressed HIV-1 infected patients

Authors: WP Bannister, A Mocroft, O Kirk, P Reiss, A d'Arminio Monforte, JM Gatell, M Fisher, H Trocha, A Rakhmanova and JD Lundgren

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O36

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Switching from enfuvirtide to etravirine – efficacy results from the etravirine expanded access programme

Authors: E Ribera, E Florence, S De Wit, A Castagna, B Ryan, H Vanaken, AM Hill and S Marks

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P37

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O333 Treatment discontinuation and virological failure amongst HIV-positive individuals starting second-line combination antiretroviral therapy (cART)

Authors: CJ Smith, FC Lampe, M Youle, MA Johnson and AN Phillips

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O37

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Efficacy and safety of an antiretroviral regimen containing etravirine plus raltegravir in HIV-1 treatment-experienced patients failing darunavir

Authors: A Canestri, C Blanc, M Wirden, G Peytavin, N Ktorza and C Katlama

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P38

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O411 HIV-TB co-infection and TB drug resistance: an emerging threat to HIV and TB programmes

Authors: GH Friedland

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O38

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Darunavir exhibits a potent activity as boosted PI in subjects on a salvage antiretroviral regimen

Authors: P Vitiello, S Ferramosca, M Lo Cicero, PDV Di Vincenzo, M Capasso, M Galli, ME Moroni and SR Rusconi

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P39

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O412 Factors associated with poor clinical outcome among HIV-infected patients with tuberculosis (TB) in Europe and Argentina. The HIV/TB collaborative study

Authors: D Podlekareva, A Mocroft, FA Post, V Riekstina, JM Miro, H Furrer, M Bruyand, A Panteleev, E Girardi, JJ Toibaro, J Caylá, R Miller, N Obel, A Skrahin, E Malashenkov, JD Lundgren…

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O39

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Raltegravir, etravirine and darunavir-ritonavir: a safe and successful rescue regimen in highly treatment-experienced HIV1-infected patients

Authors: A Imaz, S Villar del Saz, MA Rivas, A Curran, E Caballero, V Falco, M Crespo, I Ocana, M Diaz, E Ruiz de Gopegui, M Riera and E Ribera

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P40

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O413 Pharmacokinetics (PK) of once-daily etravirine (ETR) without and with once-daily darunavir/ritonavir (DRV/r) in antiretroviral-naïve HIV-1 infected adults

Authors: J Lalezari, E DeJesus, O Osiyemi, P Ruane, Z Haigney, R Ryan, B Polsonetti, TN Kakuda and J Witek

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O40

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Safety and efficacy of tipranavir co-administered with low-dose ritonavir in patients with advanced HIV-1 infection and limited treatment options

Authors: S Esser, A Moll, V Cairns, H Jaeger, S Mauss, J van Lunzen and J Goldbach

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P41

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance

Authors: P Cahn, J Altclas, M Martins, M Losso, I Cassetti, S Cox and DA Cooper

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O41

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Exposition and sequencing to antiretrovirals in HIV-1 patients with triple-class antiretroviral failure, and harbouring protease resistance mutations

Authors: JM Llibre, P Domingo, F Blanco, B Clotet, A Ocampo, JA García-Henarejos, P Geijo, C Rosa, J Hernandez-Quero and A Castro

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P42

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O415 Efficacy and safety of 48-week maintenance with QD ATV vs ATV/r (both + 2NRTIs) in patients with VL <50 c/mL after induction with ATV/r + 2NRTIs: study AI424136

Authors: JF Delfraissy, S Moreno, J Sanz-Moreno, G Carosi, V Pokrovsky, A Lazzarin, G Pialoux, A Balogh, E Vandeloise and G Leleu

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O42

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
L76V – clinically relevant resensitization of the protease inhibitors (PIs) saquinavir (SQV) and atazanavir (ATV)

Authors: J Vachta, F Wiesmann, P Braun, R Ehret, C Höhn, A Tappe and H Knechten

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P43

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O421 When to start therapy? The patient's viewpoint

Authors: G Cairns and K Alcorn

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O43

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Positive predictive factors in HIV-1 patients treated with enfuvirtide plus an OB that include an active boosted PI. Preliminary FastFuz study results

Authors: E Ribera, A Antela, JA Garcia Henarejos, JR Arribas, JA Oteo, M Lopez Gomez and E Ferrer

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P44

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O422 Do the disadvantages of late initiation of HAART persist in patients achieving and maintaining viral load (VL) suppression for a year on HAART?

Authors: LJ Waters, M Fisher, J Anderson, C Wood and CA Sabin

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O44

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Excellent short-term CD4 recovery with a PI- and NRTI-sparing regimen in triple-class failure HIV-infected patients: raltegravir, maraviroc, etravirine

Authors: S Nozza, F Visco, A Soria, L Galli, S Salpietro, N Gianotti, E Carini, A Bigoloni, G Fusetti, G Tambussi, A Lazzarin and A Castagna

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P45

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O423 Risk of new AIDS-defining events in patients with advanced immunodeficiency during suppressive HAART: results from the German ClinSurv cohort

Authors: A Zoufaly, C Kreuzberg, M An der Heiden, C Kollan, O Hamouda and J van Lunzen

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O45

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Efficacy and tolerance of combination of maraviroc with MK-0518, boosted TMC-114, TMC-125, in heavily pre-treated CCR5-positive patients

Authors: F Almasi, A Krivine, A Compangocci, B Silberman, L Belaebi and D Salmon

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P46

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O424 Resistance development in virological failures with DRV/r or LPV/r: 96-week analysis of the Phase III TITAN trial in treatment-experienced patients

Authors: S De Meyer, E Lathouwers, I Dierynck, E De Paepe, B Van Baelen, T Vangeneugden, F Tomaka, MP de Béthune and G Picchio

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O46

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Therapeutic options in heavily pretreated HIV-1 patients based on the genotypic resistance patterns

Authors: D Paraskevis, E Magiorkinis, G Magiorkinis, V Paparizos, MC Lazanas, M Chini, H Sambatakou, A Karafoulidou and A Hatzakis

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P47

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
O425 Efficacy and safety of maraviroc in treatment-experienced (TE) patients infected with R5 HIV-1: 96-week combined analysis of the MOTIVATE 1 and 2 studies

Authors: WD Hardy, R Gulick, HB Mayer, G Fätkenheuer, M Nelson, J Heera, N Rajicic and J Goodrich

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):O47

Content type: Oral presentation Published on: 10 November 2008
- View Full Text
- View PDF
Darunavir in patients who failed on fos-amprenavir: efficacy at week 48

Authors: S De Wit, M Delforge, K Kabeya, C Necsoi and N Clumeck

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P48

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
Etravirine use in clinical practice: 48-week data from a single centre cohort

Authors: C Scott, N Khatib, M Bower, BG Gazzard and M Nelson

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P49

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF
Transient therapy with quadruple NRTI provides immune stability in patients with multidrug resistant HIV-1 and no options for suppressive regimens

Authors: A Bonjoch, JM Llibre, E Negredo, J Puig, N Pérez-Álvarez, MJ Buzon, J Martinez-Picado and B Clotet

Citation: Journal of the International AIDS Society 2008 11(Suppl 1):P50

Content type: Poster presentation Published on: 10 November 2008
- View Full Text
- View PDF

Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection

Meeting abstracts

Journal of the International AIDS Society